These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
584 related articles for article (PubMed ID: 31737952)
1. CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson's from controls. Oosterveld LP; Verberk IMW; Majbour NK; El-Agnaf OM; Weinstein HC; Berendse HW; Teunissen CE; van de Berg WDJ Mov Disord; 2020 Feb; 35(2):288-295. PubMed ID: 31737952 [TBL] [Abstract][Full Text] [Related]
2. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies. van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090 [TBL] [Abstract][Full Text] [Related]
3. CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson's Disease. Oosterveld LP; Kuiper TI; Majbour NK; Verberk IMW; van Dijk KD; Twisk JWR; El-Agnaf OM; Teunissen CE; Weinstein HC; Klein M; Berendse HW; van de Berg WDJ Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198266 [TBL] [Abstract][Full Text] [Related]
4. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study. Delgado-Alvarado M; Gago B; Gorostidi A; Jiménez-Urbieta H; Dacosta-Aguayo R; Navalpotro-Gómez I; Ruiz-Martínez J; Bergareche A; Martí-Massó JF; Martínez-Lage P; Izagirre A; Rodríguez-Oroz MC Mov Disord; 2017 Jul; 32(7):1066-1073. PubMed ID: 28548309 [TBL] [Abstract][Full Text] [Related]
5. Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease. Hall S; Surova Y; Öhrfelt A; ; Blennow K; Zetterberg H; Hansson O Mov Disord; 2016 Jun; 31(6):898-905. PubMed ID: 26878815 [TBL] [Abstract][Full Text] [Related]
6. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases. Williams SM; Schulz P; Sierks MR Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448 [TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. Goldman JG; Andrews H; Amara A; Naito A; Alcalay RN; Shaw LM; Taylor P; Xie T; Tuite P; Henchcliffe C; Hogarth P; Frank S; Saint-Hilaire MH; Frasier M; Arnedo V; Reimer AN; Sutherland M; Swanson-Fischer C; Gwinn K; ; Kang UJ Mov Disord; 2018 Feb; 33(2):282-288. PubMed ID: 29205509 [TBL] [Abstract][Full Text] [Related]
8. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. Majbour NK; Vaikath NN; van Dijk KD; Ardah MT; Varghese S; Vesterager LB; Montezinho LP; Poole S; Safieh-Garabedian B; Tokuda T; Teunissen CE; Berendse HW; van de Berg WD; El-Agnaf OM Mol Neurodegener; 2016 Jan; 11():7. PubMed ID: 26782965 [TBL] [Abstract][Full Text] [Related]
9. CSF biomarkers and clinical progression of Parkinson disease. Hall S; Surova Y; Öhrfelt A; Zetterberg H; Lindqvist D; Hansson O Neurology; 2015 Jan; 84(1):57-63. PubMed ID: 25411441 [TBL] [Abstract][Full Text] [Related]
10. Measurements of auto-antibodies to α-synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease. Akhtar RS; Licata JP; Luk KC; Shaw LM; Trojanowski JQ; Lee VM J Neurochem; 2018 Jun; 145(6):489-503. PubMed ID: 29500813 [TBL] [Abstract][Full Text] [Related]
11. Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease. Abbasi N; Mohajer B; Abbasi S; Hasanabadi P; Abdolalizadeh A; Rajimehr R Mov Disord; 2018 Mar; 33(3):431-439. PubMed ID: 29436735 [TBL] [Abstract][Full Text] [Related]
12. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM; JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011 [TBL] [Abstract][Full Text] [Related]
13. Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease. Eidson LN; Kannarkat GT; Barnum CJ; Chang J; Chung J; Caspell-Garcia C; Taylor P; Mollenhauer B; Schlossmacher MG; Ereshefsky L; Yen M; Kopil C; Frasier M; Marek K; Hertzberg VS; Tansey MG J Neuroinflammation; 2017 Aug; 14(1):164. PubMed ID: 28821274 [TBL] [Abstract][Full Text] [Related]
14. Integrated Plasma and Neuroimaging Biomarkers Associated with Motor and Cognition Severity in Parkinson's Disease. Chen CH; Lee BC; Lin CH J Parkinsons Dis; 2020; 10(1):77-88. PubMed ID: 31868681 [TBL] [Abstract][Full Text] [Related]
15. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease. Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300 [TBL] [Abstract][Full Text] [Related]